Challenging a concept: Pulsed treatment regimen

Abstract

Get full access to this article

View all access options for this article.

References

Warnke

Olsson

Hartung

HP.

PML: The dark side of immunotherapy in multiple sclerosis. Trends Pharmacol Sci 2015; 36(12): 799–801.

Forster

Kury

Aktas

et al . Managing risks with immune therapies in multiple sclerosis. Drug Saf. Epub ahead of print 3 January 2019. DOI: 10.1007/s40264-018-0782-8.

Gerevini

Capra

Bertoli

et al . Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2019; 25: 1196–1201.

Berger

Aksamit

Clifford

et al . PML diagnostic criteria: Consensus statement from the AAN neuroinfectious disease section. Neurology 2013; 80(15): 1430–1438.

Richards

Surks

et al . Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol 2018; 194(3): 295–314.

Baker

Herrod

Alvarez-Gonzalez

et al . Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 2017; 74(8): 961–969.

Ceronie

Jacobs

Baker

et al . Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol 2018; 265(5): 1199–1209.

Warnke

Mausberg

Stettner

et al . Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology 2013; 81(16): 1400–1408.

Major

Yousry

Clifford

DB.

Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: A decade of lessons learned. Lancet Neurol 2018; 178: 4676–4460.

10.

Saure

Warnke

Zohren

et al . Natalizumab and impedance of the homing of CD34⁺ hematopoietic progenitors. Arch Neurol 2011; 68(11): 1428–1431.

Challenging a concept: Pulsed treatment regimen—No risk of PML?

Abstract

Get full access to this article

References